Scientists test new Auto-Injector version of skin condition drug
NCT ID NCT07367958
Summary
This early-stage study aims to compare how the body processes CT-P52 (a biosimilar version of the drug Taltz) when given through an auto-injector versus a traditional pre-filled syringe. The study will involve 218 healthy male volunteers who will receive a single dose and be monitored for about 3 months. Researchers want to see if both delivery methods work similarly in the body and are equally safe.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY MALE SUBJECTS are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.